- Home
- QCRH vs NVAX Comparison
QCRH vs NVAX Comparison
Compare QCRH & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QCRH
- NVAX
- Stock Information
- Founded
- QCRH 1993
- NVAX 1987
- Country
- QCRH United States
- NVAX United States
- Employees
- QCRH N/A
- NVAX N/A
- Industry
- QCRH Major Banks
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QCRH Finance
- NVAX Health Care
- Exchange
- QCRH Nasdaq
- NVAX Nasdaq
- Market Cap
- QCRH 1.3B
- NVAX 1.3B
- IPO Year
- QCRH 1993
- NVAX 1995
- Fundamental
- Price
- QCRH $72.03
- NVAX $8.78
- Analyst Decision
- QCRH Buy
- NVAX Buy
- Analyst Count
- QCRH 3
- NVAX 7
- Target Price
- QCRH $88.83
- NVAX $14.29
- AVG Volume (30 Days)
- QCRH 104.2K
- NVAX 4.5M
- Earning Date
- QCRH 10-22-2025
- NVAX 11-11-2025
- Dividend Yield
- QCRH 0.32%
- NVAX N/A
- EPS Growth
- QCRH N/A
- NVAX N/A
- EPS
- QCRH 6.63
- NVAX 2.54
- Revenue
- QCRH $322,873,000.00
- NVAX $1,078,718,000.00
- Revenue This Year
- QCRH N/A
- NVAX $60.81
- Revenue Next Year
- QCRH $14.12
- NVAX N/A
- P/E Ratio
- QCRH $11.28
- NVAX $3.50
- Revenue Growth
- QCRH N/A
- NVAX 9.22
- 52 Week Low
- QCRH $60.83
- NVAX $5.01
- 52 Week High
- QCRH $96.08
- NVAX $13.61
- Technical
- Relative Strength Index (RSI)
- QCRH 30.07
- NVAX 51.28
- Support Level
- QCRH $75.06
- NVAX $8.32
- Resistance Level
- QCRH $77.48
- NVAX $9.60
- Average True Range (ATR)
- QCRH 1.66
- NVAX 0.45
- MACD
- QCRH -0.60
- NVAX -0.02
- Stochastic Oscillator
- QCRH 0.00
- NVAX 34.91
About QCRH QCR Holdings Inc.
QCR Holdings Inc is a multi-bank holding company. The bank operates through segments namely Commercial Banking, Wealth Management, and all other segments. The commercial bank segment is geographically divided by markets namely Quad City Bank & Trust (QCBT), Cedar Rapids Bank & Trust (CRBT), Community State Bank (CSB) and Guaranty Bank (GB). It generates revenue in the form of interest.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.